ArticleJournal of pharmacy & bioallied sciences
Evaluation of the Immunomodulatory Activity and Protective Effect of Estragole Against Sepsis in C57BL/6 Mice.
Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Estragole (EST), a phenylpropanoid found in essential oils, exhibits anti-inflammatory, antibacterial, antioxidant, and immunomodulatory properties. Aims: This study investigated its potential protective effects against systemic infections in septic C57BL/6 mice. We evaluated leukocyte recruitment, nitric oxide production, bacterial viability in blood, and survival rates. In addition, we assessed its effects on cell viability and phagocytosis Materials and Methods: The effects of EST were evaluated both Statistical Analysis: Results are expressed as the mean ± standard error of the mean (SEM). Statistical evaluation was performed using one-way analysis of variance (ANOVA) followed by Tukey's Results: Treatment with EST (250 and 500 mg/kg, orally), administered one hour prior to sepsis induction, reduced leukocyte recruitment and nitric oxide production at the infection site, decreased the number of viable bacteria in the blood, and improved survival rates (significantly at 500 mg/kg) after seven days. Furthermore, at non-toxic concentrations (90 µg/mL), EST enhanced the phagocytic activity of neutrophils Conclusions: Estragole demonstrated immunomodulatory and antibacterial effects, strengthening immune responses and reducing mortality in septic C57BL/6 mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.